MyHealthChecked's (LON: MHC) share price is sliding after the consumer home testing healthcare firm posted a £3.8 million pre-tax loss for the year ended 31 December 2020.
The Group's loss for 2019 came in at £2.1 million.
Revenue rose to £49,480 from £31,970 the previous year.
The company described 2020 as a “transformational year” after they began delivery of a growth plan, allowing them to “begin 2021 with a clear runway ahead to revenue achievement.”
Penny McCormick, CEO of MyHealthChecked, said: “We have commenced 2021 a very different organisation to that of the previous January, and I am immensely proud of the team that formed during lockdown and gelled together with a commitment, energy and ambition for growth.
“We stand today as a team with a highly credible, compliant and successful pharmacy customer, a high street presence, a proven service, and with an operational and commercial set-up ready to deliver growth in a regulated product, poised for the needs of the market in 2021.
“With a strong pipeline outside of COVID-19 building, life after COVID is exciting, and we enter this phase with growing confidence in the road to delivery gained through the experiences and successes of 2020 and 2021 to date.”
MyHealthChecked also separately announced the appointment of Gareth Davies as Chief Financial and Operations Officer, succeeding Maddy Kennedy, who joined the Company in October 2019.
Shares of MHC are trading at 3.98p, down 5.24%
Should you invest in MyHealthChecked shares?
MyHealthChecked shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are MyHealthChecked shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies